Comparison of morphine (strong opioid) with tramadol (weak opioid) in advanced lung cancer patients with moderate to severe pain in terms of quality of life and pain relief at 3 weeks follow up

Comparison of WHO step 2 analgesic drug versus step 3 analgesic drug in Stage 4 opioid-naive lung cancer patients presenting to pain clinic with moderate to severe pain in terms of pain relief and quality of life at 3 weeks follow up: A randomized prospective study.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011093

Enrollment

Registered

2018-01-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J984- Other disorders of lung Health Condition 2: null- Stage 4 lung cancer patients with moderate to severe pain presenting to pain clinic

Interventions

Intervention1: Tramadol: Weak opioids Control Intervention1: Morphine: Strong opioids

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years 2. Either gender 3. Diagnosed with stage 4 lung cancer 4. Patients have agreed to participate in the study and have signed written informed consent. 5. Admitted or attending Palliative care OPD at IRCH 6. Patients already on Step 1 WHO analgesic ladder 7. Opioid-naÃ¯ve patients 8. NRS >4 (Moderate to severe pain) 9. Somatic, visceral or mixed pain

Exclusion criteria

Exclusion criteria: 1. Diagnosed mental illness or cognitive impairment 2. Patients refusal to give consent/assent to participate in the study 3. Patients with delirium or obtundation 4. Co-existing liver or renal diseases 5. Patients requiring intravenous(IV) drugs or IV morphine titration 6. Pure neuropathic pain

Design outcomes

Primary

Measure	Time frame
â?¢ Assessment of quality of life and pain scores in stage 4 lung cancer patients with moderate to severe pain receiving tramadol versus morphine at 3 weeks follow upTimepoint: â?¢ Assessment of quality of life and pain scores in stage 4 lung cancer patients with moderate to severe pain receiving tramadol versus morphine at 3 weeks follow up	—

Secondary

Measure	Time frame
1. Symptom burden in stage 4 lung cancer patients 2. Association between Numerical rating scale (NRS) scores and QOL 3. Overall satisfaction of lung cancer patients with treatment. 4. Percentage of patients started on tramadol but converted to morphine at 3 weeks follow up. 5. Side effects pattern with tramadol and morphine in lung cancer patients 6. Cost effectiveness Timepoint: At 1 and 3 weeks of follow up	—

Measure

Time frame

1. Symptom burden in stage 4 lung cancer patients 2. Association between Numerical rating scale (NRS) scores and QOL 3. Overall satisfaction of lung cancer patients with treatment. 4. Percentage of patients started on tramadol but converted to morphine at 3 weeks follow up. 5. Side effects pattern with tramadol and morphine in lung cancer patients 6. Cost effectiveness Timepoint: At 1 and 3 weeks of follow up

—

Countries

India

Contacts

Public ContactDr Sushma Bhatnagar

AIIMS, New Delhi

sushmabhatnagar1@gmail.com01129575209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026